Zuckerman A J
Department of Medical Microbiology, London School of Hygiene and Tropical Medicine, U.K.
J Virol Methods. 1987 Aug;17(1-2):119-26. doi: 10.1016/0166-0934(87)90074-7.
Acyclovir and suramin were examined for their efficacy alone and in combination, against duck hepatitis B virus (DHBV) in persistently infected Pekin ducks. The pharmacokinetics of acyclovir in ducks showed that the peak plasma concentration was reached 30 min after oral administration. Oral acyclovir and suramin administered intravenously suppressed the replication and production of infectious virions as measured by marked reduction of DNA polymerase activity during treatment. However, rebound of enzyme activity was observed soon after cessation of drug therapy. In contrast, sustained reduction of polymerase activity was attained by combined therapy of acyclovir followed by suramin, demonstrating a significant enhancement of anti-DHBV activity which requires confirmation in a larger experimental study. This report reviews the work with the duck model, demonstrating that it is ideal for screening antiviral compounds for treatment of infection with hepadna viruses.
研究了阿昔洛韦和苏拉明单独及联合使用对持续感染北京鸭的鸭乙型肝炎病毒（DHBV）的疗效。阿昔洛韦在鸭体内的药代动力学表明，口服给药后30分钟达到血浆峰值浓度。口服阿昔洛韦和静脉注射苏拉明可抑制感染性病毒粒子的复制和产生，治疗期间DNA聚合酶活性显著降低即表明了这一点。然而，停药后不久观察到酶活性反弹。相比之下，阿昔洛韦联合苏拉明治疗可使聚合酶活性持续降低，表明抗DHBV活性显著增强，这需要在更大规模的实验研究中得到证实。本报告回顾了在鸭模型上开展的研究工作，证明该模型是筛选用于治疗嗜肝DNA病毒感染的抗病毒化合物的理想模型。
